Objectives: To report the identification of the metallo-b-lactamase (MBL) variant VIM-19 in a Klebsiella pneumoniae clinical strain co-producing KPC-2 carbapenemase, CMY-2 cephalosporinase and CTX-M-15 extended-spectrum b-lactamase.
Introduction
During the last few years, carbapenem resistance has been increasingly reported in Klebsiella pneumoniae and is largely attributed to the production of carbapenem-hydrolysing enzymes, such as metallo-b-lactamase (MBL) and K. pneumoniae carbapenemase (KPC) types.
1,2
K. pneumoniae isolates producing KPC enzymes have become increasingly prevalent on the East Coast of the USA since 2001. 2 They have also caused outbreaks in Israel, and have recently become emerging public health concerns in several regions worldwide, such as China, Latin America and Greece. 2 The dissemination of KPC producers poses a significant threat for carbapenem activity, considering the increasing rates also of MBL-producing K. pneumoniae.
MBLs of the VIM group have been identified in different countries as a source of several nosocomial K. pneumoniae outbreaks.
1, 2 The VIM group currently includes 23 variants, clustered into three evolutionary lineages, represented by VIM-1, VIM-2 and VIM-7 (www.lahey.org/studies). In 2009, a new bla VIM gene variant, designated bla VIM-19 , was detected in enterobacterial pathogens from Algiers and characterized by two research groups. 3, 4 In both descriptions, the gene bla VIM-19 was located as the first gene cassette in a class 1 integron with an unidentified 3 ′ extremity. 3, 4 In addition, Rodriguez-Martinez et al. 4 have shown that the amino acid substitutions by which VIM-19 differs from the closely resembled VIM-1 and VIM-4 enzymes confer increased carbapenem hydrolytic activity. During the same year, K. pneumoniae producing this potent VIM-19 carbapenemase, along with KPC-2, CMY-2 and CTX-M-15 enzymes, was identified in another Mediterranean region, Greece (GenBank accession number FJ 915116). The present report documents this worrisome evolution.
Materials and methods
Bacterial isolates and phenotypic testing K. pneumoniae strain KP1935 was recovered in May 2008 from a urinary tract infection of a 64-year-old female patient hospitalized at Serres General Hospital, Greece. MICs for the clinical and transconjugant strains of several b-lactams, aminoglycosides, ciprofloxacin, trimethoprim, tetracycline, tigecycline and colistin were determined by agar dilution. The isolate was phenotypically screened for carbapenemase production by performing combined tests using four discs of meropenem, one without and the other three with EDTA, phenylboronic acid (PBA) or both EDTA and PBA. 5 K. pneumoniae ATCC 13883, Pseudomonas aeruginosa ATCC 27853 and isolates from our laboratory collection that produce KPC, VIM and extended-spectrum b-lactamases (ESBLs) were used as controls in susceptibility assays.
PCR assays and DNA sequencing
The detection of broad-spectrum b-lactamase genes (KPC, CMY and other plasmidic AmpC-like genes, OXA-48 carbapenemase, MBLs, and ESBLs of TEM, SHV and CTX-M types) was sought by PCR using consensus primers that were specific for each enzyme group. 6 Isolates from our collection that were previously characterized were used as controls in the PCR assays. For integron mapping, PCR assays combining primers specific for conserved 5
′ -CS and 3 ′ -CS sequences with primers for bla VIM , aacA, dfr, aadA, qacED1 and sul genes were performed. PCR products of the genes tested and also of the bla VIM -carrying integron were sequenced on both strands. The bla KPC -flanking region PCR was mapped using a series of successive primers. 7 
Conjugation assays and plasmid analysis
Filter mating experiments were performed using Escherichia coli 26R793 (lac 2 , rif r ) as recipient. Selection of the transconjugants was made on MacConkey agar plates containing rifampicin (100 mg/L) and either ampicillin (40 mg/L) or ertapenem (0.5-1 mg/L). Plasmid isolation was performed with the QIAfilter Plasmid Maxi Kit (Qiagen) and with a standard alkaline lysis protocol, using E. coli 39R861 as the standard plasmid control. The plasmid DNA bands of the transconjugants were extracted from the agarose gel, and used as templates in PCR for bla KPC , bla VIM , bla CMY and bla TEM genes.
Results
The strain KP1935 was resistant or intermediate to all b-lactams, including carbapenems, with imipenem, meropenem and ertapenem MICs being 32, 16 and 64 mg/L, respectively. It also exhibited resistance to almost all alternative antimicrobials, including colistin (MIC 16 mg/L), and was susceptible to only tigecycline (MIC 2 mg/L) ( Table 1 ). The simultaneous presence of both MBL and KPC carbapenemases was indicated by a positive combined-disc test using meropenem with both EDTA and PBA, while meropenem discs containing EDTA or PBA 6 were negative. PCR for b-lactamase genes showed that KP1935 was positive for bla TEM , bla CTX-M , bla CMY , bla VIM and bla KPC genes, and negative for the remaining genes tested, including all bla SHV variants. Sequencing analysis identified bla TEM-1 , bla CTX-M-15 , bla CMY-2 , bla VIM-19 and bla KPC-2 alleles. PCR and sequencing using primers 5 ′ -CS and 3 ′ -CS in various combinations with primers for bla VIM , aacA, aadA and dfrA1 genes revealed a new class 1 integron with a structure similar to that carrying the close variant gene bla VIM-4 in an Enterobacter cloacae isolate from Greece. 8 The bla VIM-19 gene cassette is located downstream of the attI1 recombination site, followed by an aacA6 cassette, a dfrA1 cassette, an aadA1 cassette and the 3 ′ -CS, containing qacED1 and sulI (Figure 1 ). PCR mapping of the bla KPC -flanking region showed that this gene was located in a Tn4401 transposon similar to that found in K. pneumoniae isolates previously. VIM-19 in a KPC-2-, CMY-2-and CTX-M-15-possessing K. pneumoniae
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Repeated mating experiments yielded transconjugant colonies with MICs that, compared with the MICs for the recipient strain E. coli 26R793, were elevated for penicillins, cephalosporins and carbapenems. Phenotypic testing of many transconjugant colonies showed that some of them were positive in the combined-disc test using meropenem and boronic acid, while others were positive using meropenem and EDTA. PCR assays showed that all boronic acid-positive transconjugant colonies tested were positive for bla KPC and bla TEM genes and negative for bla VIM , bla CMY and bla CTX-M , while all EDTA-positive colonies tested were positive for bla VIM and bla CMY and negative for bla KPC , bla CTX-M and bla TEM . Transconjugant colonies that were PCR-positive for bla CTX-M were not detected after repeated mating experiments and testing numerous colonies. Plasmid analysis of the clinical strain KP1935 revealed two plasmids of 70 and 150 kb, while the bla VIM -and bla CMY -bearing transconjugants had a single plasmid of 150 kb and the bla KPC -and bla TEM -bearing transconjugants had a single plasmid of 70 kb. PCR, using as template the gel-extracted plasmid DNA band of the transconjugants, confirmed the carriage of the bla KPC and bla TEM genes on the 70 kb plasmid, and of the bla VIM and bla CMY genes on the 150 kb plasmid. The MICs for the bla KPC -positive and the bla VIM -positive transconjugant colonies of the antibiotics tested are shown in Table 1 .
Discussion
In the present report, the novel MBL bla VIM-19 was detected in a clinical strain of K. pneumoniae that also harboured bla TEM-1 , bla CMY-2 , bla KPC-2 and bla CTX-M-15 . The gene bla VIM-19 differs from bla VIM-4 by one amino acid residue at position 215 (Asn215Lys, standard class B b-lactamase numbering scheme) and from bla VIM-1 by two amino acid residues (Asn215Lys and Ser228Arg) that increase the carbapenemase activity of the VIM-19 enzyme compared with VIM-1. 4 It could be postulated that VIM-19 has arisen under carbapenem pressure in our hospitals, where VIM-1-or VIM-4-producing microorganisms are common. 8, 9 Alternatively, this novel variant may have arisen independently and be common in our regions. The latter possibility is supported by the detection of bla VIM-19 in a distantly located Mediterranean country 3, 4 and also by the wide occurrence of the close variant gene bla VIM-4 in remote countries. 8, 10 Indeed, the emergence of bla VIM-19 in a class 1 integron with a gene content similar to that of an integron detected previously in Greece, but including bla VIM-4 instead of bla VIM-19 , 8 underlines the continuous evolution of these important determinants. It should be noted that a similar integron carrying bla VIM-4 in an E. cloacae isolate was harboured in a different plasmid (40 kb) that also included the ESBL gene bla SHV-2a , 8 in contrast with the bla VIM-19 -carrying integron, indicating that the dissemination of a single plasmid is probably not the cause of VIM-4 or VIM-19 spread.
The study strain KP1935 had higher carbapenem MICs compared with most K. pneumoniae clinical strains from Greece that produce VIM or KPC as single carbapenemases. 6, 9 Furthermore, the VIM-19-possessing transconjugants had MICs of imipenem (8 mg/L) and meropenem (2 mg/L) that were similar to those of other VIM-19-producing laboratory strains, 3,4 being higher than those of VIM-1-producing laboratory strains. 4, 9 This observation further supports the enhanced carbapenemase activity of VIM-19 relative to VIM-1.
In tertiary care Greek hospitals, K. pneumoniae isolates that produce MBLs or, more recently, KPC carbapenemases are commonly recovered from clinical infections. 6, 9 The current detection of VIM-19 along with KPC-2 in our strain is only the second description of a K. pneumoniae strain that produced two different carbapenemases after the appearance of VIM-1-and KPC-2-producing K. pneumoniae. 11 Considering that the combination of a potent VIM variant along with KPC and CTX-M-15 ESBL inactivates all clinically available b-lactams, a further spread of the respective strains or plasmids may have even more serious consequences in the treatment of nosocomial infections.
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